This is a recorded version of the AACC webinar “Biomarkers of Heart Failure: Current Status and Future Promise,” which was originally held February 14, 2012. BNP and NT-proBNP have become popular tests for diagnosing acute dyspnea and possible congestive heart failure (CHF) in the ED, and can be particularly useful when the clinical presentation is difficult to confirm. Laboratorians are also investigating new markers that show great promise for diagnosing and managing this common cardiac disease. Dr. Robert Christenson explains what the evidence indicates about using the natriuretic peptides—BNP and NT-proBNP—for heart failure diagnosis, risk stratification and management and what the data show regarding the equivalence between Mid Region proADM and the natriuretic peptides. He also discusses the role of ST2 in optimizing patient management.